News

News 14.12.2021 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced a collaboration with Novartis in the form of a...

News 13.12.2021 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 12, 2021 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that preclinical studies confirm that ensovibep maintains...

News 06.12.2021 ZURICH-SCHLIEREN, Switzerland and CONCORD Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced the presentation of results from the Phase 2a study of ensovibep for COVID-19 patients as...

News 03.12.2021 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 03, 2021 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced a research collaboration with University of Bern, to advance the development of the Company’s wholly...

News 30.11.2021 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners, a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today issued a statement regarding the recently identified SARS-CoV-2 variant, termed Omicron (B.1.1.529)1. The...